Evenity (Romosozumab) Pediatric (<12) Caregiver Administration Guidance

Is Romosozumab Approved for Children Under 12?

Romosozumab is not approved by the FDA for any patient under 18 years of age. The FDA granted approval in April 2019 exclusively for postmenopausal women with osteoporosis at high fracture risk, based on adult trial data. Any use in a child under 12 is off-label and must be supervised by a pediatric endocrinologist or metabolic bone specialist. [1]

That regulatory gap matters because caregivers sometimes encounter romosozumab prescriptions after a specialist has exhausted approved options. Children with severe osteogenesis imperfecta (OI), chronic corticosteroid-induced osteoporosis, or immobilization-related bone loss may be candidates when bisphosphonate therapy has failed or is contraindicated.

Why the Off-Label Route Exists

The bone-forming mechanism of romosozumab, inhibiting sclerostin to simultaneously increase bone formation and reduce bone resorption, makes it theoretically attractive for pediatric conditions characterized by defective bone matrix. Published case reports describe its use in children with OI types III and V. A 2022 case series in the Journal of Clinical Endocrinology and Metabolism documented measurable lumbar spine bone mineral density gains in pediatric OI patients receiving romosozumab off-label. [2]

What Caregivers Should Confirm Before the First Dose

Before handling a prefilled syringe at home, caregivers must verify three things with the prescribing specialist.

1. The child has had a baseline echocardiogram or cardiology clearance, given the boxed cardiovascular warning.
2. A baseline serum calcium, phosphate, and 25-hydroxyvitamin D level has been obtained. Hypocalcemia is a known romosozumab adverse effect and is especially risky in children.
3. The pharmacy has dispensed the correct adult 105 mg/1.14 mL prefilled syringe, because no pediatric formulation exists. Dose adjustments, if any, are calculated by the specialist based on weight.

Understanding the Boxed Warning: Cardiovascular Risk

The FDA-mandated boxed warning states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. Romosozumab is contraindicated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months. [1]

In the ARCH trial (N=4,093), romosozumab was associated with a statistically higher rate of serious cardiovascular adverse events compared to alendronate (2.5% vs. 1.9%; P<0.05). [3] That trial enrolled postmenopausal women, not children, but the biological mechanism that may mediate cardiovascular risk, including effects on vascular calcification via sclerostin pathways, is not age-specific.

Cardiovascular Screening for Pediatric Candidates

A child under 12 being considered for romosozumab should have a formal cardiovascular risk assessment. Children with conditions that raise cardiac risk, such as Marfan syndrome, congenital heart disease, or long-term corticosteroid use, require specialist-to-specialist communication between the metabolic bone team and cardiology before any dose is given.

The Endocrine Society's 2017 clinical practice guideline on bone disease in pediatric patients states: "Pharmacologic intervention should be reserved for children with clear evidence of clinically significant bone fragility and should be initiated by specialists with expertise in pediatric metabolic bone disease." [4] This directly applies to romosozumab decisions in patients under 12.

Preparing the Injection: Step-by-Step Caregiver Instructions

Supplies Needed

Caregivers need two prefilled syringes or autoinjectors of romosozumab 105 mg/1.14 mL (both given at the same visit), alcohol swabs, a puncture-resistant sharps container, and clean gauze. Do not use cotton balls soaked in povidone-iodine; iodine can interfere with site healing.

Warming the Syringe

Remove both syringes from the refrigerator 30 minutes before injection. Cold solution causes more injection-site pain and may affect drug dispersion. Do not microwave, run under hot water, or place near a heating pad. Hold the syringe gently in your palm.

Choosing and Rotating the Injection Site

Approved subcutaneous sites are the abdomen (at least 2 inches from the navel), the front of the thigh, or the outer upper arm. In younger children with less subcutaneous tissue, the abdomen is often preferred because of the larger surface area available. Rotate the exact site each month; a simple written log prevents repeated injection into the same spot, which increases the risk of localized lipodystrophy and poor absorption. [5]

The Injection Sequence

Administer both 105 mg injections consecutively at the same visit, not on different days. The prescribing information specifies both injections complete one monthly dose. Clean each site with an alcohol swab and let it air-dry for 10 seconds. Pinch the skin gently (especially in thin children), insert the needle at a 45-degree angle for children with minimal subcutaneous tissue or 90 degrees if the tissue is adequate, depress the plunger slowly, and withdraw the needle at the same angle used for insertion. Apply gentle pressure with gauze for 10 seconds; do not rub.

Discard each syringe immediately into the sharps container. Never recap needles. [1]

Storage, Handling, and Syringe Inspection

Romosozumab must stay refrigerated at 2 to 8°C (36 to 46°F). A single prefilled syringe may be kept at room temperature up to 30°C (86°F) for a maximum of 30 days in its original carton, after which it must be discarded even if unused. Never freeze the syringe; freezing destroys the protein structure of the biologic and renders it ineffective. [1]

Before each injection, inspect the solution through the prefilled syringe window. The liquid should be clear to slightly opalescent and colorless to pale yellow. Discard any syringe that contains visible particles, is cloudy, or appears discolored. Check the expiration date printed on the carton; expired product must go into pharmaceutical waste, not household garbage.

Transport to a clinic or pharmacy should use an insulated bag with a gel ice pack. Avoid placing the syringe directly against ice.

Dosing Frequency and Treatment Duration

The standard adult romosozumab regimen consists of 12 monthly doses. After completing 12 injections, the prescribing information and American College of Rheumatology guidance indicate that patients should transition to an antiresorptive agent, typically a bisphosphonate or denosumab, to preserve the bone gains achieved. [6] Stopping romosozumab without follow-on therapy results in rapid bone mineral density loss, sometimes returning to near-baseline within 12 months.

For off-label pediatric use, the specialist will define whether the full 12-dose course applies or whether a shorter course is appropriate based on DXA scan response and fracture history. Caregivers should never extend treatment beyond the specialist-specified number of doses without a new clinical review.

Tracking Monthly Doses at Home

A practical caregiver tracking framework involves three records:

1. A dated injection log (site used, lot number from syringe label, any immediate reactions).
2. A monthly symptom diary covering jaw pain, new fractures or pain, muscle cramps (possible hypocalcemia), and any chest pain or neurological symptoms.
3. A laboratory result file for each monthly or quarterly calcium, phosphate, and alkaline phosphatase measurement ordered by the clinic.

This three-part documentation system gives the specialist the data needed at each follow-up visit to make dose-continuation decisions.

Managing Hypocalcemia in Pediatric Patients

Hypocalcemia is the most common clinically significant adverse effect of romosozumab, occurring because increased bone formation pulls calcium rapidly into new bone matrix. In adults, the FRAME trial (N=7,180) reported that pre-existing hypocalcemia or vitamin D deficiency substantially amplifies this risk. [7]

Children have a smaller total calcium reservoir and faster bone turnover than adults, which makes them potentially more vulnerable to post-dose hypocalcemic episodes.

Signs Caregivers Should Recognize

Symptoms of acute hypocalcemia in a child include perioral tingling or numbness, hand or foot cramps (carpopedal spasm), muscle twitching, irritability, and in severe cases, laryngospasm or seizures. Any of these findings after a romosozumab injection require immediate medical evaluation.

Vitamin D and Calcium Supplementation Protocol

The prescribing information requires that patients have adequate calcium and vitamin D before starting romosozumab. For children under 12, the National Institutes of Health Office of Dietary Supplements recommends 1,000 mg of elemental calcium daily for ages 4 to 8 and 1,300 mg for ages 9 to 13, with 600 IU of vitamin D daily as the baseline. [8] The specialist may prescribe higher supplemental doses depending on baseline 25-hydroxyvitamin D levels. Caregivers should give calcium and vitamin D supplements at a different time of day from any other medications that affect absorption.

Injection-Site Reactions and What to Do

Injection-site reactions are among the most frequently reported adverse events with romosozumab in clinical trials, affecting approximately 5% of adult patients in the FRAME study. [7] These reactions include redness, bruising, pain, and swelling at the injection site. Most resolve within 3 to 5 days without treatment.

Apply a cool compress for 10 minutes immediately after injection if the child is uncomfortable. Oral acetaminophen at weight-appropriate dosing may be used for pain. Avoid ibuprofen or other NSAIDs on injection day if the specialist has concerns about bone healing, as NSAIDs may theoretically interfere with prostaglandin-mediated bone formation signaling.

Seek prompt medical attention if the injection site develops spreading redness, warmth, or discharge beyond 48 hours, which could indicate a secondary infection.

Monitoring Schedule During Treatment

Laboratory Tests

The prescribing specialist should order serum calcium and phosphate at baseline and at approximately 1 month after the first injection, then quarterly. In children with pre-existing hypocalcemia risk, more frequent monitoring is appropriate. Alkaline phosphatase serves as a marker of bone formation activity and can confirm the drug is working as expected.

Bone Density Imaging

DXA scanning is the standard tool for tracking treatment response. Because growing bones complicate DXA interpretation, a pediatric radiologist or metabolic bone specialist should review all scans. Repeat DXA is typically obtained at 6 months for children on off-label regimens, with a final scan at the end of the 12-dose course before transitioning therapy. [9]

Osteonecrosis of the Jaw Monitoring

Osteonecrosis of the jaw (ONJ) is a rare but recognized risk with bone-modifying agents. The prescribing information for romosozumab includes this as a potential adverse effect. Before starting treatment, the child should have a dental examination; any invasive dental work should be completed before the first dose and avoided during active treatment where possible. [1] Caregivers should report any jaw pain, swelling, or tooth loosening to both the prescribing specialist and the child's dentist.

Missed Doses and Rescheduling

If a monthly injection is missed, administer it as soon as the caregiver can arrange it with the clinical team. After a missed dose is given, the schedule resets to that new date. Do not double up by giving four syringes (two months' worth) in a single session. The specialist will decide whether a missed month affects the overall 12-dose plan or whether an extra month should be added.

Storing an extra pair of syringes at home is not recommended unless the specialist specifically authorizes a home supply, because improper storage is common and the medication is costly. Most caregivers coordinate each month's supply through a specialty pharmacy with cold-chain delivery.

Talking With Your Child About Monthly Injections

Younger children often experience significant anxiety around needles. The American Academy of Pediatrics recommends several evidence-based strategies for procedural pain management in children, including topical anesthetic cream (EMLA or LMX-4) applied 45 to 60 minutes before injection, distraction techniques such as blowing bubbles or watching a preferred video, and caregiver coaching using calm, neutral language rather than reassurances that explicitly mention pain ("it won't hurt that much"). [10]

Apply topical anesthetic to both planned injection sites. Use a small adhesive dressing after each injection if the child finds it comforting. Consistent monthly routines reduce anticipatory anxiety over successive doses.

Contraindications and Situations Requiring Specialist Contact

Caregivers must contact the prescribing specialist immediately (and go to an emergency department if the child has chest pain or neurological symptoms) in any of these situations.

• Chest pain, shortness of breath, or one-sided weakness after any injection.
• Jaw pain, swelling, or ulceration at any point during the treatment course.
• Signs of severe hypocalcemia (muscle spasm, laryngospasm, seizure).
• Fever above 38.5°C (101.3°F) within 24 hours of injection, which may indicate a systemic reaction.
• The child undergoes surgery or a significant dental procedure during the treatment course.

Romosozumab should be paused before elective surgical procedures at the discretion of the surgical team and the prescribing specialist, given the theoretical cardiovascular risk in perioperative settings.

Transition Therapy After Completing 12 Doses

Bone mineral density gains achieved with romosozumab diminish quickly without follow-on treatment. The ARCH trial demonstrated that transitioning to alendronate after romosozumab preserved and further increased spine and hip BMD compared to alendronate alone. [3] In pediatric populations, the follow-on agent choice depends on the underlying condition. Children with OI commonly continue intravenous bisphosphonate therapy (pamidronate or zoledronic acid), which has the most strong pediatric safety data. [11]

Caregivers should attend the final-dose clinic appointment prepared to discuss the transition plan. The specialist will order a post-treatment DXA, reassess fracture risk, and prescribe the antiresorptive regimen before the last romosozumab injection date, so there is no gap in bone protection.